期刊文献+

骨髓纤维化的发病机制及临床表现 被引量:8

Advances in pathogenesis and clinical manifestations of myelofibrosis
下载PDF
导出
摘要 骨髓纤维化是骨髓增殖性肿瘤的一种,预后差,生存期短。最近的研究对其发病的分子机制、临床表现及并发症都有进展,对此种疾病的临床诊断、治疗及预后评估都有帮助。本文对以上内容的研究进展进行综述。 Myelofibrosis is a kind of myeloproliterative neoplasms,prognosis is poor,overall survival is short. Recent studies on molecular mechanism of its pathogenesis,clinical manifestations and complications have new progress,this kind of disease in the clinical diagnosis,treatment and prognosis assessment is helpful. This paper reviewd research progress on the above content.
出处 《现代肿瘤医学》 CAS 2016年第6期998-1001,共4页 Journal of Modern Oncology
基金 黑龙江省教委课题(编号:JXOOQ5和07050030051) 黑龙江省教育厅科学技术研究项目(编号:12511339和12541530)
关键词 骨髓纤维化 发病机制 临床表现 并发症 myelofibrosis pathogenesis clinical manifestations complication
  • 相关文献

参考文献27

  • 1Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF) ,post polycythemia vera myelofibrosis (post -PV MF), post essential thrombocythemia myelofibrosis (post ET MF), blast phase PMF (PMFBP) : consensus on terminology by ~the Interna- tional Working Group for myelofibrosis research and treatment ( IWG - MRT) [ J]. Leuk Res ,2007,31 (6) :737 -740.
  • 2Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mu- tations and pathogenesis of myeloproliferative neoplasms [ J ]. Blood,2011,118 (7) : 1723 - 1735.
  • 3Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms[ J], Blood ,2011,118 : 1610 - 1621.
  • 4Anand S, Huntly B. Disordered signaling in myeloproliferative neo- plasms[ J]. Hematol Oncol Clin North Am ,2012,26 : 1017 - 1035.
  • 5Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013,369(25) :2391 -2405.
  • 6Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013,369(25) :2379 -2390.
  • 7Richter R, Jochheim - Richter A, Ciuculescu F, et al. Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor ceils [ J ]. Stem Ceils Dev, 2014,23 : 1959 - 1974.
  • 8Claudia Augelloa, Umberto Gianellia, Rossella Falconec, et al. PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis [ J ]. Leukemia Research, 2015,39 ( 2 ) ~ 236 -241.
  • 9Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424,a JAK1 and JAK2 inhibitor, in myelofibrosis [ J ]. N Engl J Med,2010,363(12) :1117 -1127.
  • 10Ayalew Tefferi. Primary myelofibrosis : 2014 update on diagnosis, risk - stratification, and management [ J ]. Am J Hematol,2014,89 (9) :915 -925.

同被引文献58

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部